‘Game changer’ semaglutide halves diabetes risk from obesity

According to a recent article in Medscape, the treatment of people with obesity (but without diabetes) with the glucagon-like peptide-1 (GLP-1) agonist semaglutide led to beneficial changes in body mass index (BMI), glycemic control, and other clinical measures.

This collectively cut the calculated risk for possible future development of Type 2 diabetes in study participants by more than half, based on data from two pivotal trials that compared semaglutide with placebo. The findings “suggest that semaglutide could help prevent Type 2 diabetes in people with overweight or obesity,” said W. Timothy Garvey, MD, in a presentation at the European Association for the Study of Diabetes 2022 Annual Meeting.

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags